Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPER-OSA 1: once-monthly berobenatide in adults with obstructive sleep apnea and overweight or obesity receiving PAP therapy
jRCT2031260628Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Jan 2027
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS), Overweight and obesity comparing Berobenatide with Placebo (2 arms). Primary endpoint: Change from baseline in apnea-hypopnea index. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
berobenatide
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)Overweightobesity
Beyond the preview
Go deeper on jRCT2031260628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260628.